BHC (Bausch Health) Debt-to-Asset : 0.84 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BHC Bausch Health Companies Inc BHC
58 GF Score
Price $6.51
GF Value $7.44
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bausch Health Debt-to-Asset?

Bausch Health BHC +2.68% 58 Debt-to-Asset is 0.84 as of Jun. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.44 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Bausch Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $881 Mil. Bausch Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $19,898 Mil. Bausch Health's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $24,794 Mil. Bausch Health's debt to asset for the quarter that ended in Jun. 2026 was 0.84.

Bausch Health  (NYSE:BHC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bausch Health Debt-to-Asset Related Terms

Bausch Health Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Bausch Health's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Debt-to-Asset Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.81 0.82 0.82 0.79

Bausch Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.78 0.79 0.85 0.84

BHC vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch Health Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bausch Health's Debt-to-Asset falls into.


BHC
58GF Score
Bausch Health Companies Inc BHC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bausch Health's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(236 + 20615) / 26366
=0.79

Bausch Health's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(881 + 19898) / 24794
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.84 mean?
Bausch Health (BHC) has a Debt-to-Asset of 0.84 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Bausch Health and its competitors.
Is Bausch Health's Debt-to-Asset too high?
Bausch Health's current Debt-to-Asset is 0.84. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Debt-to-Asset compare to ZTS?
Bausch Health's Debt-to-Asset of 0.84 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Bausch Health and its competitors. Bausch Health's current Debt-to-Asset is 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.44, compared to a current price of $6.51 — trading 12.5% below its estimated fair value. The current Debt-to-Asset is 0.84. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Bausch Health (BHC), the current Debt-to-Asset is 0.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of $6.51 is trading 12.5% below its estimated GF Value™ of $7.44. GuruFocus considers Bausch Health to be Modestly Undervalued.

Key valuation signals for BHC:

  • Debt-to-Asset: 0.84
  • GF Value™: $7.44 vs. price of $6.51 (12.5% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score

Get the complete analysis for BHC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.51
Price
$7.44
GF Value